Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Recruiting · NCT05998642 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-15 | NCT05998642 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Canadian Cancer Trials Group | 73 |
| Janssen Inc. | 6 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Allan Blair Cancer Centre | Regina | Canada | 76 |
| Arthur J.E. Child Comprehensive Cancer Centre | Calgary | Canada | 45 |
| BCCA - Vancouver | Vancouver | Canada | 22 |
| CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) | Québec | Canada | 5 |
| Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton | Canada | 60 |
| Ottawa Hospital Research Institute | Ottawa | Canada | 46 |
| The Research Institute of the McGill University | Montreal | Canada | 10 |
| University Health Network | Toronto | Canada | 52 |